A renewed regulatory opening and a clinical setback sent two biotech stocks in opposite directions in October. Biohaven gained ground after the FDA agreed to review its rare disease resubmission, while ArriVent BioPharma plunged after its lead candidate missed in a Phase 3 cancer study, then suffered another selloff despite encouraging early results for a separate asset.

Here, BioSpace analyzes these two sizeable stock shifts and the developments driving the activity. This monthly series is not intended to be a comprehensive review of all public biotech movement.

Who’s hot: Biohaven (BHVN)

The FDA has accepted Biohaven’s twice-rebuffed rare disease drug for review, a regulatory decision…